BTIG Downgrades Liquidia Stock to Neutral Amid Legal Setback
Liquidia Corporation's stock faced renewed pressure on Thursday after BTIG downgraded it from Buy to Neutral. The downgrade followed a more than 50% drop in the previous session, triggered by an adverse court ruling that favored rival United Therapeutics. The legal decision weakened Liquidia’s competitive position and raised concerns about its future prospects. As a result, investors reacted negatively, leading to continued declines in stock price despite the downgrade being seen as somewhat expected given recent volatility. BTIG's revised stance reflects uncertainty around Liquidia's ability to recover market confidence following this setback.
